BioMarin Pharma's (BMRN) Q2 Revenue Tops Views
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.53 +0.15%
Revenue Growth %: +32.7%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +32.7%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($2.61), may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $300.1 million versus the consensus estimate of $278.16 million.
GUIDANCE:
BioMarin Pharma sees FY2016 revenue of $1.1-1.15 billion, versus prior guidance of $1.05-1.1 billion and the consensus of $1.09 billion.
| Item | ||||
| Provided April 28, 2016 | Updated August 4, 2016 | |||
| Total BioMarin Revenues | $1,050 to $1,100 | $1,100 to $1,150 | ||
| Vimizim Net Product Revenue | $315 to $340 | $340 to $360 | ||
| Naglazyme Net Product Revenue | $290 to $320 | Unchanged | ||
| Kuvan Net Product Revenue | $320 to $350 | $340 to $360 |
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
